An Open-Label, Single Center, Nonrandomized, Dose-Escalation Phase 1 Study to Evaluate Safety and Tolerability of SHR-1210 in Subjects With Advanced Melanoma
Phase of Trial: Phase I
Latest Information Update: 25 Nov 2016
At a glance
- Drugs Camrelizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 19 Apr 2016 Status changed from not yet recruiting to recruiting.
- 18 Apr 2016 New trial record